These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31845095)

  • 1. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
    Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
    Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of QT prolongation with serotonin reuptake inhibitors.
    Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
    Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.
    Maljuric NM; Noordam R; Aarts N; Niemeijer MN; van den Berg ME; Hofman A; Kors JA; Stricker BH; Visser LE
    Br J Clin Pharmacol; 2015 Oct; 80(4):698-705. PubMed ID: 25966843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.
    Beach SR; Kostis WJ; Celano CM; Januzzi JL; Ruskin JN; Noseworthy PA; Huffman JC
    J Clin Psychiatry; 2014 May; 75(5):e441-9. PubMed ID: 24922496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study.
    van Haelst IM; van Klei WA; Doodeman HJ; Warnier MJ; De Bruin ML; Kalkman CJ; Egberts TC
    J Clin Psychiatry; 2014 Jan; 75(1):15-21. PubMed ID: 24345304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
    Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
    BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?
    Vieweg WV; Hasnain M; Howland RH; Hettema JM; Kogut C; Wood MA; Pandurangi AK
    Am J Med; 2012 Sep; 125(9):859-68. PubMed ID: 22748401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
    Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
    J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
    Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged QTc interval due to escitalopram overdose.
    Mohammed R; Norton J; Geraci SA; Newman DB; Koch CA
    J Miss State Med Assoc; 2010 Dec; 51(12):350-3. PubMed ID: 21370605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the risk of QT prolongation among SSRIs.
    Funk KA; Bostwick JR
    Ann Pharmacother; 2013 Oct; 47(10):1330-41. PubMed ID: 24259697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapeutic determinants for QTc interval prolongation in Japanese patients with mood disorder.
    Okayasu H; Ozeki Y; Fujii K; Takano Y; Saeki Y; Hori H; Horie M; Higuchi T; Kunugi H; Shimoda K
    Pharmacopsychiatry; 2012 Nov; 45(7):279-83. PubMed ID: 22592502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Citalopram is not safe from the cardiac point of view--SSRI preparations can cause prolonged QTc time].
    Odar-Cederlöf I; Hjelmström P; Jersenius I; Andersson M; Rasmanis G; Bergman U
    Lakartidningen; 2006 Apr 5-11; 103(14):1112-4. PubMed ID: 16681095
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Petry N; Lupu R; Gohar A; Larson EA; Peterson C; Williams V; Zhao J; Wilke RA; Hines LJ
    Pharmacogenomics; 2019 Apr; 20(5):343-351. PubMed ID: 30983508
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Ponzone R; Biglia N; Sismondi P
    J Natl Cancer Inst; 2004 Jun; 96(11):883-4; author reply 884-5. PubMed ID: 15173274
    [No Abstract]   [Full Text] [Related]  

  • 17. Should We be Worried About QTc Prolongation Using Citalopram? A Review.
    Hutton LMJ; Cave AJ; St-Jean R; Banh HL
    J Pharm Pract; 2017 Jun; 30(3):353-358. PubMed ID: 26763342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database.
    Park SI; An H; Kim A; Jang IJ; Yu KS; Chung JY
    Expert Opin Drug Saf; 2016 Aug; 15(8):1013-9. PubMed ID: 27276059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.
    Tseng PT; Lee Y; Lin YE; Lin PY
    Gen Hosp Psychiatry; 2012; 34(2):210.e13-5. PubMed ID: 22133983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of relationship between plasma levels of escitalopram and QTc-interval length.
    Carceller-Sindreu M; de Diego-Adeliño J; Portella MJ; Garcia-Moll X; Figueras M; Fernandez-Vidal A; Queraltó JM; Puigdemont D; Álvarez E
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):815-822. PubMed ID: 28116499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.